285 related articles for article (PubMed ID: 29850617)
1. High-Risk Leukemia: Past, Present, and Future Role of NK Cells.
Mavers M; Bertaina A
J Immunol Res; 2018; 2018():1586905. PubMed ID: 29850617
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
3. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
[TBL] [Abstract][Full Text] [Related]
4. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
[TBL] [Abstract][Full Text] [Related]
5. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
7. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
Moretta A; Locatelli F; Moretta L
Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
[TBL] [Abstract][Full Text] [Related]
8. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).
Falco M; Pende D; Munari E; Vacca P; Mingari MC; Moretta L
HLA; 2019 Apr; 93(4):185-194. PubMed ID: 30828978
[TBL] [Abstract][Full Text] [Related]
10. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C
J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.
Ruggeri L; Mancusi A; Burchielli E; Perruccio K; Aversa F; Martelli MF; Velardi A
Semin Cancer Biol; 2006 Oct; 16(5):404-11. PubMed ID: 16916611
[TBL] [Abstract][Full Text] [Related]
12. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
13. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
14. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
15. Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors.
Baltner K; Kübler A; Pal M; Balvociute M; Mezger M; Handgretinger R; André MC
Int Immunol; 2017 Nov; 29(9):423-429. PubMed ID: 29099970
[TBL] [Abstract][Full Text] [Related]
16. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.
Ruggeri L; Capanni M; Mancusi A; Urbani E; Perruccio K; Burchielli E; Tosti A; Topini F; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2004; 33(3):216-21. PubMed ID: 15528134
[TBL] [Abstract][Full Text] [Related]
17. NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia.
Locatelli F; Pende D; Falco M; Della Chiesa M; Moretta A; Moretta L
Trends Immunol; 2018 Jul; 39(7):577-590. PubMed ID: 29793748
[TBL] [Abstract][Full Text] [Related]
18. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
19. Markers and function of human NK cells in normal and pathological conditions.
Del Zotto G; Marcenaro E; Vacca P; Sivori S; Pende D; Della Chiesa M; Moretta F; Ingegnere T; Mingari MC; Moretta A; Moretta L
Cytometry B Clin Cytom; 2017 Mar; 92(2):100-114. PubMed ID: 28054442
[TBL] [Abstract][Full Text] [Related]
20. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]